diethyl 4-(bromomethyl)benzylphosphonate | 108228-81-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diethyl 4-(bromomethyl)benzylphosphonate
• 英文别名: Phosphonic acid, [[4-(bromomethyl)phenyl]methyl]-, diethyl ester；1-(bromomethyl)-4-(diethoxyphosphorylmethyl)benzene
• CAS: 108228-81-5
• 化学式: C₁₂H₁₈BrO₃P
• 分子量: 321.151
• InChiKey: POTHJMIRYNDASN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  diethyl 4-(bromomethyl)benzylphosphonate 在 sodium tetrahydroborate 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.5h， 生成 diethyl {4-[3-hydroxy-2-(hydroxymethyl)propyl]phenyl}methylphosphonate
  参考文献：
  名称：

  Enzymatic desymmetrization of prochiral 2-benzyl-1,3-propanediol derivatives: A practical chemoenzymatic synthesis of novel phosphorylated tyrosine analogues

  摘要：

  (Phosphonomethyl)phenylalanine (Pmp) and (phosphonodifluoromethyl)phenylalanine (F(2)Pmp) as well as their beta-amino acid congeners were prepared as a protecting variant amenable to the peptide synthesis from readily available 2-benzyl-1,3-propandiols possessing either a diethylphosphonomethyl- or diethylphosphonodifluoromethyl functionality at the para-position via the lipase-catalyzed desymmetrization. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(98)00586-9
• 作为产物：
  描述：

  4-甲基苄基膦酸二乙酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 3.0h， 以76%的产率得到diethyl 4-(bromomethyl)benzylphosphonate
  参考文献：
  名称：

  Synthesis of monophosphonic acid ligands with a phenanthroline core

  摘要：

  The efficient synthesis of two diimine ligands incorporating one benzyl phosphonate group and a phenanthroline core is described. These functionalized ligands constitute a new type of linkers in hybrid organic-in organic materials based on inorganic oxides and metallic complexes. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.07.067

文献信息

• PHOSPHATE DERIVATIVES AND USE THEREOF
  申请人：ZHU Qing

  公开号：US20210030773A1

  公开（公告）日：2021-02-04

  The present invention discloses a compound with the following formula (I), or a tautomer, mesomer, racemate, enantiomer, and diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug molecule thereof, wherein D is selected from: The invention further discloses the use of the compound in the preparation of drugs for preventing and/or treating cancers, and the use of the compound in the preparation of drugs for inhibiting cancer metastasis. The compound of the present invention can effectively inhibit the proliferation and metastasis of cancer cells by adjusting the acidity of a tumor microenvironment to achieve a better effect in clinical cancer treatment, and has broad application prospects.

  本发明公开了具有以下式（I）的化合物，或其互变异构体、共振异构体、外消旋体、对映体和非对映异构体，或其混合形式，或其药学上可接受的盐，或其前药分子，其中D从以下中选择： 该发明还公开了该化合物在制备用于预防和/或治疗癌症的药物中的用途，以及该化合物在制备用于抑制癌症转移的药物中的用途。本发明的化合物可以通过调节肿瘤微环境的酸度来有效抑制癌细胞的增殖和转移，从而在临床癌症治疗中取得更好的效果，并具有广阔的应用前景。
• COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
  申请人：Wu Tom Yao Hsiang

  公开号：US20110053893A1

  公开（公告）日：2011-03-03

  The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

  这项发明提供了一类新型化合物，包括这类化合物的免疫原组合物和药物组合物，以及利用这类化合物治疗或预防与Toll样受体7相关的疾病或紊乱的方法。在一个方面，这些化合物可用作辅助剂，以增强疫苗的有效性。
• Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists
  作者：Daniel F. Ortwine、Thomas C. Malone、Christopher F. Bigge、James T. Drummond、Christine Humblet、Graham Johnson、Garry W. Pinter

  DOI：10.1021/jm00086a004

  日期：1992.4

  The preparation and binding affinity of a series of tetrahydroisoquinoline carboxylic acids at the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor is described, together with a molecular modeling analysis of NMDA agonists and antagonists. Using published NMDA ligands, the active analogue mapping approach was employed in the generation of an agonist pharmacophore model. Although known

  描述了一系列四氢异喹啉羧酸在谷氨酸受体的N-甲基-D-天冬氨酸（NMDA）亚型上的制备和结合亲和力，以及对NMDA激动剂和拮抗剂的分子模型分析。使用公开的NMDA配体，在激动剂药效团模型的产生中采用了活性类似物作图方法。尽管可以将已知的竞争性拮抗剂（例如CPP（1））叠加到激动剂模型上，但要克服它们与相同受体位点结合的假设，可以使用独立的建模方法来得出单独的药效团模型。竞争性拮抗剂模型的开发涉及一种逐步方法，其中包括定义PO3H2受体相互作用的优选几何形状，多重构象搜索，以及确定体积和电子公差。对该模型进行了详细描述，与观察到的强效NMDA拮抗剂的亲和力一致，并为已知拮抗剂AP5，AP6和AP7的亲和力观察到的周期性提供了解释。比较了激动剂和拮抗剂模型的特征，并提出了关于这两类化合物的受体相互作用性质的假说。本文报道的药效基团模型与可容纳激动剂和拮抗剂配体的NMDA受体上的单个识别位点一致
• Adsorption of immunopotentiators to insoluble metal salts
  申请人：Singh Manmohan

  公开号：US09315530B2

  公开（公告）日：2016-04-19

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以被吸附到不溶性金属盐，如铝盐，以修改它们的药代动力学、药效动力学、肌肉内滞留时间和/或免疫刺激效应。免疫增强剂被改性以引入一种基团，如膦酸盐基团，可以介导吸附。这些改性化合物即使以吸附形式投递，也可以保留或改善它们在体内的免疫活性。
• [EN] BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE POUR LE TRAITEMENT D'UNE INFECTION PAR FILOVIRUS
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2018050771A1

  公开（公告）日：2018-03-22

  The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

  本发明涉及含有苯并咪唑骨架的化合物，以及利用这些化合物治疗病毒性疾病。该发明还涉及包含上述化合物作为活性成分的药物组合物。特别是，本发明涉及含有苯并咪唑骨架的化合物用于治疗丝状病毒或逆转录病毒，尤其是用于治疗埃博拉病毒或艾滋病毒。